NSW BREAST CANCER INSTITUTE ADOPTS IMPEDIMED’S L-DEX
November 20th 2008 08:31
Tuesday November 18, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: CYTOPIA UP 17%, PHYLOGICA DOWN 29%
* VICTORIAN GOVERNMENT FUNDS ZEBRA FISH RESEARCH UNIT
* LABTECH CO-FOUNDER, DIRECTOR PAUL MARIANI DIES
* PRANA PROTOTYPE BLOCKS ANAESTHETIC PATHOLOGY IN MICE
* NSW BREAST CANCER INSTITUTE ADOPTS IMPEDIMED’S L-DEX
* VIRALYTICS AGM DIVIDED; ALL RESOLUTIONS PASSED
* GOODBYE HEARTWARE LTD, G’DAY HEARTWARE INTERNATIONAL INC
* KARMELSONIX’ NADAISAN LOGARAJ QUITS BOARD, DROPS 1m OPTIONS
* AUSBIOTECH BIO-BEERS TOMORROW
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
IMPEDIMED
Impedimed says the New South Wales Breast Cancer Institute has implemented a program of screening for lymphoedema using its technology.
Impedimed chief executive officer Greg Brown told Biotech Daily that the company had sold the lymphoedema testing equipment to the Breast Cancer institute and had expected the Institute to conduct a trial.
Mr Brown said the company had sold the Institute four units and received ongoing income from the sale of electrodes for the units.
Mr Brown said he was pleasantly surprised to learn that the NSW Breast Cancer Institute had announced “an innovative lymphoedema screening program using bio-impedance spectroscopy to monitor women before surgery and during the first two years after surgery to detect and treat early stages of lymphoedema and prevent long-term severe lymphoedema symptoms”.
In a media release Impedimed said it was “delighted that a prestigious institution like the [New South Wales Breast Cancer Institute] has recognized the benefits of using the L-Dex approach to aid their health professionals in the pre-operative care of breast cancer patients for the early clinical assessment and prevention of lymphoedema”.
In the media release Mr Brown said that the use of L-Dex (lymphoedema index) technology at the Institute and other centres around the world represented “an ongoing emergence of a new clinical standard of care for medical professionals in their management of breast cancer patients in an attempt to prevent lymphoedema”.
“It is particularly gratifying to see just how Australian medical care is on the leading edge of change,” Mr Brown said.
“It is truly a proactive approach to medicine and demonstrates how the Australian healthcare system is very focused on addressing all the needs of breast cancer patients from day one,” he said.
He said the Institute was well-recognized and “having such a reputable institute using our technology for this pro-active care model is both exciting and influential in changing medical practice globally”.
Impedimed was untraded at 65 cents.
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 18 |
| Vote |
Add To: 
subscribe to this blog